Results 171 to 180 of about 1,841,501 (298)

UHPLC/MS Profile and Antimalarial Potency of <i>Enantia chlorantha</i> Oliv. (Annonaceae) Stem Bark Aqueous Extract. [PDF]

open access: yesAdv Pharmacol Pharm Sci
Messi Betene AN   +14 more
europepmc   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

open access: yesMolecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone   +11 more
wiley   +1 more source

Interdisciplinary Approach at the Border Between Hematology and Cardiology

open access: yesJournal of Interdisciplinary Medicine, 2017
Opincariu Diana, Rat Nora
doaj   +1 more source

Magnetic dipole imaging of magnetite nanoparticles in brain tissue. [PDF]

open access: yesRSC Adv
Kaub L   +8 more
europepmc   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

open access: yesMolecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti   +3 more
wiley   +1 more source

Rat Spine Fusion Models for Preclinical Research: Opportunities and Challenges. [PDF]

open access: yesACS Biomater Sci Eng
Lobao A   +4 more
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Home - About - Disclaimer - Privacy